If you've been following kratom news in 2026, you've probably seen the phrase "7-OH" appearing more often — in FDA enforcement actions, in state ban legislation, in news coverage of kratom-related deaths. Understanding what 7-OH is, how it differs from standard kratom leaf, and why the distinction matters is increasingly important for anyone using kratom or working on stopping.
TL;DR: Kratom products fall into three broad categories: leaf powder (the traditional form, lower potency, primarily mitragynine), extracts (concentrated, variable potency, higher 7-OH ratio), and dedicated 7-hydroxymitragynine (7-OH) products (full opioid agonist activity, significantly higher risk profile). These are not equivalent products. The FDA's 2026 enforcement actions and most state kratom bans are primarily targeting the extract and 7-OH category, not leaf powder. If you're using kratom — or working on stopping — knowing which category your product falls into changes almost everything: withdrawal severity, risk profile, taper approach, and clinical considerations.
The three categories
Leaf powder
Leaf powder is the closest commercially available product to traditional kratom use. It's made from dried, ground Mitragyna speciosa leaves and contains the full naturally occurring alkaloid profile — primarily mitragynine (~66% of alkaloids), with 7-hydroxymitragynine (7-OH) as a minor constituent (typically under 2% of the alkaloid profile by weight).
Leaf powder is consumed as tea, mixed into drinks, or packed into capsules. A typical "dose" for an experienced user is 3-8 grams.
The effects of leaf powder are primarily driven by mitragynine, which is a partial opioid receptor agonist — meaning it binds to opioid receptors but activates them less fully than a full agonist like morphine. This partial agonism is one reason why kratom leaf powder's overdose risk profile differs from full opioid agonists.
Extracts
Kratom extracts are concentrates — leaf powder or tea processed to increase the alkaloid concentration per gram of product. They're sold as powders, liquids, resins, and shots, typically labeled with numbers indicating concentration ("10x," "50x") or total alkaloid percentages.
The concentration claims on kratom extract products are often unreliable. A product labeled "50x" may or may not actually contain 50 times the alkaloid concentration of an equivalent weight of leaf powder — labeling standards in the unregulated kratom market are inconsistent. What extract products reliably produce is a higher-potency effect per gram and a less predictable alkaloid ratio than leaf powder.
Specifically: the extraction process can selectively concentrate 7-OH relative to its natural proportion in the leaf. Products marketed for potency often have a 7-OH ratio significantly above the 2% found in natural leaf, which shifts the pharmacological character toward full opioid agonism.
A common dosing error with extracts: users who are accustomed to leaf-powder gram weights apply the same mental model to extracts and inadvertently consume a much higher effective dose. This is one of the mechanism by which extract use escalates to problematic patterns more rapidly than leaf-powder use.
7-OH products
7-hydroxymitragynine (7-OH) products represent a distinct category that has emerged in the commercial kratom market, particularly in the last 2-3 years. These are products that specifically isolate, concentrate, or synthetically produce 7-OH — sometimes labeled as "7-OH kratom," "7-OH mitragynine," or sold in concentrated liquid shot form.
7-OH has full mu-opioid receptor agonist activity. The FDA's 2018 assessment estimated it to be approximately 13 times more potent than morphine at the receptor level. Unlike mitragynine (the partial agonist that dominates natural leaf), 7-OH activates opioid receptors fully — which is why high-7-OH products carry a risk profile much closer to prescription opioids than to natural kratom.
The FDA has taken specific enforcement action against products making explicit claims about 7-OH content, and several state bans specifically target 7-OH rather than mitragynine. From a regulatory standpoint, high-concentration 7-OH products are increasingly treated as drug analogues under the Federal Analogue Act rather than as botanical dietary supplements.
Why the distinction matters: a comparison
| | Leaf Powder | Extract | 7-OH Products | |---|---|---|---| | Primary alkaloid | Mitragynine | Mitragynine + elevated 7-OH | 7-OH concentrated | | Opioid receptor activity | Partial agonist | Partial to full agonist (variable) | Full agonist | | Typical dose | 3-10g | 0.1-2g (varies widely) | Often dosed in mg | | Potency predictability | Moderate | Low (labeling unreliable) | Low | | Dependence development | Moderate | Faster, more severe | Faster, more severe | | Withdrawal severity | Moderate | Higher | Significantly higher | | Overdose risk | Low to moderate | Moderate to high | High (especially with other substances) | | FDA status | Unscheduled; import alerts for some products | Greater scrutiny; import alerts | Active enforcement action; drug analogue concern | | Naloxone responsive | Partially | More responsive | Fully responsive |
The FDA enforcement landscape in 2026
The FDA's position on kratom has evolved significantly since the 2016 attempted scheduling. The current approach is not a blanket prohibition on all kratom but a focused enforcement on specific product categories — particularly 7-OH-containing products and products making health claims.
Key FDA actions as of 2026:
- Ongoing import alerts covering specific kratom manufacturers and products, primarily targeting those with adulteration, health claims, or high 7-OH content
- Warning letters to manufacturers of 7-OH-specific products
- Increased scrutiny under the Federal Analogue Act for synthetically concentrated 7-OH products
- 2023 analysis documenting 7-OH concentrations in commercial products far exceeding natural leaf ratios
The practical implication: leaf powder from reputable vendors in states where kratom is legal remains in a different regulatory situation than extract and 7-OH products. This doesn't mean leaf powder is FDA-approved or without risk — it isn't — but the enforcement trajectory is clearly directed at the concentrated products.
What this means for withdrawal and tapering
If you're working on stopping kratom, knowing which category your primary product falls into changes the approach significantly.
Stopping or tapering from leaf powder
The standard kratom taper protocol was designed primarily for leaf-powder users. The 10-20% reduction every 3-7 days is based on relatively predictable mitragynine alkaloid content per gram of leaf powder. Withdrawal follows the documented timeline — acute phase of 4-7 days, PAWS period of 2-6 months.
Stopping or tapering from extracts
Tapering from extracts is harder for two reasons: the alkaloid concentration per gram is unpredictable, and the 7-OH ratio may be elevated above natural leaf levels, shifting the withdrawal character toward a fuller opioid profile.
The recommended approach for extract users is a two-phase strategy: first transition from extract to leaf powder (using the leaf powder dose equivalent of your extract dose, adjusted for potency — starting slightly higher and reducing to find a comfortable level), then taper the leaf powder using the standard protocol. This takes longer but gives you a predictable, calibrated substrate to taper from.
Stopping or tapering from high-7-OH products
High-7-OH products present the most complex withdrawal picture. Because 7-OH is a full opioid agonist, the withdrawal from high-7-OH use resembles opioid withdrawal more closely than standard kratom withdrawal — including potentially more severe anxiety, physical symptoms, and craving. The cold-turkey approach has a lower success rate for this product category.
Clinical support is worth involving for high-7-OH users considering stopping. Buprenorphine has evidence as a bridge medication for opioid withdrawal and is likely more appropriate for high-7-OH withdrawal than for standard leaf-powder withdrawal. A telehealth appointment with a MAT-experienced clinician gives you access to that option.
How to identify what you're actually using
If you're currently using kratom and aren't sure which category your product falls into, a few signals:
Leaf powder indicators:
- Product is a green, brown, or off-white powder sold by the gram or pound
- Packaging typically shows a powder consistency and is labeled by strain name (e.g., Maeng Da, Bali, Green Malay)
- No explicit potency multiplier claims
Extract indicators:
- Labels with "X" potency claims (10x, 25x, 50x)
- Dark-colored resin or concentrated powder
- Significantly smaller serving size than leaf powder (0.5-2g versus 5-10g)
- Higher price per gram than leaf powder
7-OH indicators:
- Product explicitly advertises "7-OH," "7-hydroxymitragynine," or "MIT45" (a common 7-OH-concentrated product line)
- Sold in liquid shot form (similar to energy-shot products)
- Price substantially higher than leaf powder per equivalent dose
- Product makes explicit potency claims on a per-dose rather than per-gram basis
If you're uncertain, the KCPA tracker from the American Kratom Association lists vendors whose products have been tested under KCPA standards — which includes alkaloid-ratio testing that distinguishes leaf powder from extracts.
The harm-reduction summary
The most practical harm-reduction information about kratom product types is this: the product category you're using matters more than the quantity per dose.
A person using 8 grams of leaf powder daily is in a different risk situation than a person using 4 MIT45 liquid shots (a high-7-OH product). The leaf-powder user has a more predictable withdrawal profile, a lower overdose risk, and a cleaner taper path. The 7-OH user has a higher dependence burden, a more complex withdrawal, and a risk profile that warrants clinical involvement.
This is not a judgment about one choice being morally better than the other. It's information that changes what you do next.
If you're currently using extract or 7-OH products and considering stopping, the starting point is transitioning to leaf powder before beginning a taper — not because leaf powder is "clean" or "better," but because it's a known quantity you can work with.
Coach Aria is a digital coaching program for people working on kratom recovery. The product you've been using shapes the withdrawal timeline and the support approach. Coach Aria's kratom recovery program is calibrated to where you're starting from — including for people working down from extracts and 7-OH products — with day-by-day structure for the taper and post-acute period. It runs privately on your phone.